Literature DB >> 17589958

Hepatitis C virus RNA kinetics: drug efficacy and the rate of HCV-infected cells loss.

Harel Dahari, Alan S Perelson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17589958      PMCID： PMC4171160          DOI： 10.3748/wjg.v13.i21.3020

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


× No keyword cloud information.
  6 in total

1.  Antiviral therapy in HCV decompensated cirrhosis: to treat or not to treat?

Authors:  Miquel Navasa; Xavier Forns
Journal:  J Hepatol       Date:  2006-11-27       Impact factor: 25.083

2.  Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

Authors:  A U Neumann; N P Lam; H Dahari; D R Gretch; T E Wiley; T J Layden; A S Perelson
Journal:  Science       Date:  1998-10-02       Impact factor: 47.728

Review 3.  New kinetic models for the hepatitis C virus.

Authors:  Alan S Perelson; Eva Herrmann; Florence Micol; Stefan Zeuzem
Journal:  Hepatology       Date:  2005-10       Impact factor: 17.425

4.  Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy.

Authors:  Jose-Eymard Medeiros-Filho; Isabel-Maria-Vicente-Guedes de Carvalho Mello; Joao-Renato-Rebello Pinho; Avidan-U Neumann; Fernanda de Mello Malta; Luiz-Caetano da Silva; Flair-Jose Carrilho
Journal:  World J Gastroenterol       Date:  2006-12-07       Impact factor: 5.742

5.  Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy.

Authors:  Harel Dahari; Arthur Lo; Ruy M Ribeiro; Alan S Perelson
Journal:  J Theor Biol       Date:  2007-03-14       Impact factor: 2.691

6.  Triphasic decline of hepatitis C virus RNA during antiviral therapy.

Authors:  Harel Dahari; Ruy M Ribeiro; Alan S Perelson
Journal:  Hepatology       Date:  2007-07       Impact factor: 17.425
  6 in total
  5 in total

1.  Potential treatment options and future research to increase hepatitis C virus treatment response rate.

Authors:  Veronica Tencate; Bruno Sainz; Scott J Cotler; Susan L Uprichard
Journal:  Hepat Med       Date:  2010-10

2.  Hepatitis C Viral Kinetics in Special Populations.

Authors:  Harel Dahari; Jennifer E Layden-Almer; Alan S Perelson; Thomas J Layden
Journal:  Curr Hepat Rep       Date:  2008

3.  A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease.

Authors:  Harel Dahari; Jennifer E Layden-Almer; Eric Kallwitz; Ruy M Ribeiro; Scott J Cotler; Thomas J Layden; Alan S Perelson
Journal:  Gastroenterology       Date:  2009-01-01       Impact factor: 22.682

4.  Type I interferon rapidly restricts infectious hepatitis C virus particle genesis.

Authors:  Luke W Meredith; Michelle J Farquhar; Alexander W Tarr; Jane A McKeating
Journal:  Hepatology       Date:  2014-10-27       Impact factor: 17.425

5.  Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.

Authors:  Valeria Cento; Thi Huyen Tram Nguyen; Domenico Di Carlo; Elisa Biliotti; Laura Gianserra; Ilaria Lenci; Daniele Di Paolo; Vincenza Calvaruso; Elisabetta Teti; Maddalena Cerrone; Dante Romagnoli; Michela Melis; Elena Danieli; Barbara Menzaghi; Ennio Polilli; Massimo Siciliano; Laura Ambra Nicolini; Antonio Di Biagio; Carlo Federico Magni; Matteo Bolis; Francesco Paolo Antonucci; Velia Chiara Di Maio; Roberta Alfieri; Loredana Sarmati; Paolo Casalino; Sergio Bernardini; Valeria Micheli; Giuliano Rizzardini; Giustino Parruti; Tiziana Quirino; Massimo Puoti; Sergio Babudieri; Antonella D'Arminio Monforte; Massimo Andreoni; Antonio Craxì; Mario Angelico; Caterina Pasquazzi; Gloria Taliani; Jeremie Guedj; Carlo Federico Perno; Francesca Ceccherini-Silberstein
Journal:  PLoS One       Date:  2017-05-18       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.